Evan Levine

Chairman and CEO

PsyBio Therapeutics

Evan Levine is an assertive and insightful leader encompassing over three decades of in-depth expertise in biotechnology and drug development, executive supervision, strategic ventures, asset management and the institutional investment business. His proficiencies include initiating, restructuring, and managing corporate infrastructure with knowledge, skill and a proven track record of delivering extraordinary returns to investors and shareholders as well as partners, employers and employees. He is adept at launching and reorganizing companies in various stages of development as well as originating and managing investment products including hedge funds, private equity capital vehicles, and NFA commodities / futures funds. Mr. Levine has served on the public and private boards of over one dozen companies in roles that include Chairman of the Board, Executive Chairman, Vice Chairman, Chief Executive Officer, Audit Committee Chairman, Nominating / Governance / Compensation Committee Member, and Trustee.

Evan M. Levine is currently Chairman and Chief Executive Officer of PsyBio Therapeutics Corp., an integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates produced by genetically modified bacteria intended for the treatment of mental health challenges and other human disorders. PsyBio has full translational capabilities with both industrial and academic laboratories including a dedicated vivarium. The PsyBio team has extensive experience in drug discovery and development based on synthetic biology, metabolic engineering, medicinal chemistry and clinical pharmacology as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Mr. Levine was responsible for the building of the corporate infrastructure of the Company, acquiring the key platform technology, funding an institutional financing round led by US venerated dedicated health care funds and taking the company public on the Toronto Venture Exchange.

Prior and relevant to Mr. Levine’s activities at PsyBio Therapeutics, he served as Chief Executive Officer of ADVENTRX Pharmaceuticals Inc., a publicly traded biotechnology company focused on the development of oncology and antiviral drug candidates. At ADVENTRX, Mr. Levine led a restructuring financing transaction and purchased controlling interest in the Company for a pre-market valuation of approximately $700,000 and under his leadership, the Company was uplisted to the American Stock Exchange, raised over $80 million dollars including a $20 million round led by Carl Icahn, conducted clinical trials on three different continents including a pivotal phase 3 in the US, and had multiple institutional research analysts covering the company which resulted in the stock trading at a valuation high of over $500 million.

Prior to launching ADVENTRX, Mr. Levine spent the first half of his career in the investment management and banking business. He served as Managing Partner and Chief Investment Officer at Brown Simpson Asset Management LLC, a $500 million private equity fund, that invested in negotiated structured investments in public healthcare and technology companies. Mr. Levine also served as Senior Vice President of Convertible Sales and Trading at Dillon Read and Vice President of Convertible Bond Trading at Hambrecht & Quist where in both roles he augmented derivative investment banking by managing an active hedged portfolio in multiple domestic and foreign securities.